Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.093
Sell
RSI(14)
21.778
Sell
STOCH(KDJ)(9,3,3)
15.048
Neutral
ATR(14)
0.164
High Vlolatility
CCI(14)
-81.265
Neutral
Williams %R
90.873
Oversold
TRIX(12,20)
-2.335
Sell
StochRSI(14)
100.000
Buy
Search
Spero Therapeutics Inc
SPROAdd to Watchlist
1.195USD
+0.015+1.27%
Close 07-28 16:00（ET）Quotes delayed by 15 min
69.18MMarket Cap
4.30P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+1.27%
5 Days
-13.41%
1 Month
-47.12%
6 Months
-46.41%
Year to Date
-48.71%
1 Year
-48.04%
Key Figures
1.180Open
1.280High
1.60MVolume
4.30P/E TTM
--P/E Dynamic
--Dividend TTM
2.77%Turnover Ratio
1.180Prev. Close
1.150Low
1.46MTurnover
LossP/E Static
1.31P/B
0.00%Div Yield TTM
22.28%ROA
3.22052wk High
0.38Volume Ratio
-68.57MNet Profit
57.89MShares
0.2777EPS TTM
1.46Beta
35.12%ROE
1.80052wk Low
11.02%Amplitude
100.00%Gross Margin
69.18MMarket Cap
-11.79Reward/Risk
4.05%Risk Rate
TradingKey Stock Score of Spero Therapeutics Inc
Currency: USD Updated: 2026-07-28Key Insights
Spero Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 118 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 4.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Spero Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Spero Therapeutics Inc Highlights
StrengthsRisks
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Growing
The company is in a growing phase, with the latest annual income totaling USD 66.80M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 4.30, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 11.81M shares, decreasing 9.85% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 47.65K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.23.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
4.000
Target Price
+236.13%
Upside Space
Spero Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
1
analysts
Hold
Current Rating
4.000
Target Price
+236.13%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Spero Therapeutics Inc
SPRO
1
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
1.199
Sell
MA10
1.366
Sell
MA20
1.746
Sell
MA50
2.264
Sell
MA100
2.409
Sell
MA200
2.378
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Spero Therapeutics Inc Info
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Ticker SymbolSPRO
CompanySpero Therapeutics Inc
CEORajavelu (Esther)
Websitehttps://sperotherapeutics.com/
Shareholders
Related Instruments
+1.98%
+0.31%
+1.71%
+2.50%
+0.83%
+2.37%
+4.42%
+2.57%
+2.92%
+2.37%
+1.72%
+2.35%
+3.47%
+3.33%
+4.61%
0.00%
+4.24%
+0.60%
+1.34%
-1.93%Popular Instruments
FAQs
What is the current price of Spero Therapeutics Inc (SPRO)?
The current price of Spero Therapeutics Inc (SPRO) is 1.20.
What is the symbol of Spero Therapeutics Inc?
The ticker symbol of Spero Therapeutics Inc is SPRO.
What is the 52-week high of Spero Therapeutics Inc?
The 52-week high of Spero Therapeutics Inc is 3.22.
What is the 52-week low of Spero Therapeutics Inc?
The 52-week low of Spero Therapeutics Inc is 1.80.
What is the market capitalization of Spero Therapeutics Inc?
The market capitalization of Spero Therapeutics Inc is 69.18M.
Is Spero Therapeutics Inc (SPRO) currently rated as Buy, Hold, or Sell?
According to analysts, Spero Therapeutics Inc (SPRO) has an overall rating of signal_hold, with a price target of 4.00.
What is the Earnings Per Share (EPS TTM) of Spero Therapeutics Inc (SPRO)?
The Earnings Per Share (EPS TTM) of Spero Therapeutics Inc (SPRO) is 0.15.